Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort study.

Fecha de publicación: 27/05/2023 Fecha Ahead of Print: 27/05/2023

Autores de IIS La Fe

Roberto Pedro Díaz Beveridge

Autor

Participantes ajenos a IIS La Fe

Ochenduszko, Sebastian
Garcia Sanchez, Javier
Fita MJJ
Gonzalez-Barrallo, Ines
Herrero Colomina, Julio
Mujika, Karmele
Martinez, Silverio Ros
Lafuente, Blanca Sanchez
Tomas, Alberto Cunquero
Jaime, Alfonso Berrocal
Cerezuela Fuentes, Pablo
Fra, Pablo Luna
Peeters, Alicia Gervas
Meana Garcia, Jose Andres
García MAA
Altozano, Javier Perez
Cancela, Maria
Puchades, Almudena Mateu
Roca, Francisco Ferrando
Maiques, Inmaculada Maestu

Grupos

Investigación Clínica y Traslacional en Cáncer

Abstract

Anti-programmed death-1 (anti-PD1) treatment has significantly improved outcomes of advanced melanoma with a considerable percentage of patients achieving complete response (CR). This real-world study analyzed the feasibility of elective anti-PD1 discontinuation in advanced melanoma patients with CR and evaluated factors related to sustained response. Thirty-five patients with advanced cutaneous or primary unknown melanoma with CR to nivolumab or pembrolizumab from 11 centers were included. Mean age was 66.5 years, and 97.1% had ECOG PS 0-1. 28.6% had =3 metastatic sites with 58.8% having M1a-M1b disease; 8.6% had liver and 5.7% had brain metastases. At baseline, 80% had normal LDH, and 85.7% had a neutrophil-to-lymphocyte ratio =3. 74.3% of patients had CR confirmed in PET-CT. Median duration of anti-PD1 was 23.4 months (range 1.3-50.5). 24 months after therapy discontinuation, 91.9% of patients were progression-free. Estimated PFS and OS at 36, 48, and 60 months from the start of anti-PD1 were 94.2%, 89.9%, 84.3%, and 97.1%, 93.3%, 93.3%, respectively. Antibiotics use after anti-PD1 discontinuation increased the odds of progression (OR 16.53 [95% CI 1.7, 226.03]). The study confirms the feasibility of elective anti-PD1 discontinuation in advanced melanoma patients with CR and favorable prognostic factors at baseline.

Datos de la publicación

ISSN/ISSNe:: 1755-1471, 1755-148X
Tipo:: Article
Páginas:: 388-398
DOI:: 10.1111/pcmr.13093
PubMed:: 37243929
Enlace a otro recurso:: www.scopus.com
Factor de Impacto:: 1,234 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Keywords

anti-programmed death-1; complete response; immunotherapy; melanoma; outcomes; treatment discontinuation